Bal Pharma Limited has submitted a formal clarification to both the National Stock Exchange of India Limited (NSE) and BSE Limited regarding significant movement in the company's stock price. This communication was prompted by specific inquiries from the exchanges: NSE Letter Ref No: NSE/CM/Surveillance/17537 and BSE Letter Ref No: L/SURV/ONL/PV/SJ/2026-2027 /4239, both dated September 10, 2026.
The company explicitly states that it does not possess any price-sensitive information or material information that could result in, or has resulted in, significant movement in the price of the company's scrip. The company confirms that all required disclosures under SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 have been made within the stipulated time period.
As of the date of this letter (September 10, 2026), the company confirms there is no event, information, or announcement that needs to be reported to the stock exchanges. The management attributes the volatility in the stock price purely to natural market forces and prevailing market conditions, explicitly stating that the company management is in no way connected with the movement in share price.
The company reiterates its commitment to adherence with compliance requirements under Listing Regulations and other applicable laws, and confirms it will continue to make disclosures to stock exchanges as and when required.
The document is digitally signed by Shreepada ML, Company Secretary and Compliance Officer (ICSI Membership No: A66681), on September 10, 2026 at 18:01:02 IST.